ICAM1 and atherosclerosis: In this trial, oxidized low‐density lipoproteins including the mRNA production of pro‐inflammatory mediators such as IL‐6, ICAM‐1, VCAM‐1, and TNF‐α were used to induce inflammation, which was reduced by luteolin via suppressing STAT3, a critically important therapeutic target in controlling atherosclerosis.